Combining entacapone with levodopa/DDCI improves clinical status and quality of life in Parkinson's Disease (PD) patients experiencing wearing-off, regardless of the dosing frequency: Results of a large multicentre open-label study

Journal of Neural Transmission

Volumn 111, Issue 8, 2004, Pages 1053-1063

  Onofrj, M ^a,g   Thomas, A ^a   Vingerhoets, F ^b   Martin, W ^c   Gimenez Roldan S ^d   Azulay, J P ^e   Bernhard, G ^f   Schmidt, W ^f   Markabi, S ^f  

^a Servizio di Neurofisiopatologia   (Italy)

^b Service de Neurologie   (Switzerland)

^c UNIVERSITY OF ALBERTA   (Canada)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e TIMONE HOSPITAL   (France)

^f NOVARTIS PHARMA AG   (Switzerland)

^g Ospedale Civile   (Italy)

Author keywords

Entacapone; Levodopa; Parkinson's disease; Wearing off

Indexed keywords

DOPA DECARBOXYLASE INHIBITOR; ENTACAPONE; LEVODOPA;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DYSKINESIA; FATIGUE; FEMALE; HALLUCINATION; HEALTH STATUS; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; TIME; TREATMENT OUTCOME; URINE COLOR; VOMITING;

EID: 3843063551     PISSN: 03009564     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00702-004-0149-4     Document Type: Article

References (30)

1. Agid Y, Olanow CW, Mizuno Y (2002) Levodopa: why the controversy? Lancet 360: 575
2. Brooks DJ, Sagar HS and the UK-Irish Entacapone Study Group (2003) Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease. A randomized, placebo-controlled, double-blind six-month study. J Neurol Neurosurg Psychiatry 74: 1064-1072
3. Durif F, Devaux I, Pere JJ, Delumeau JC, Bourdeix on behalf of the F-01 Study Group (2001) Efficacy and tolerability of entacapone as adjunctive therapy to levodopa in patients with Parkinson's disease and end-of-dose deterioration in daily medical practice: an open, multicenter study. Eur Neurol 45: 111-118
4. GPDS (2002) Factors impacting on quality of life in Parkinson's disease: results from an international survey. Mov Disord 17: 60-67
5. Heikkinen H, Saraheimo M, Antila S, Ottoila P, Pentikainen PJ (2001b) Pharmacokinetics of entacapone, a peripherally acting catechol-O- methyltransferase inhibitor, in man. A study using a stable isotope technique. Eur J Clin Pharmacol 56: 821-826
6. Hubble J, Schumock G, Markowitz J, Gutterman E (2000) Entacapone and quality of life in patients with Parkinson's disease: results of the Response Initiative Program. Neurol Rev [Suppl]: 11-16
7. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N (1997) The PDQ-8: development and validation of a short-form Parkinson's disease questionnaire. Psychol Health 12: 805-814
8. Kaakkola S (2000) Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson's disease. Drugs 59: 1233-1250
9. Keranen T, Gordin A, Karlsson M, Korpela K, Pentikainen PJ, Rita H, Schultz E, Seppala L, Wikberg T (1994) Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 46: 151-157
10. Koller WC, Pahwa R (1994) Treating motor fluctuations with controlled-release levodopa preparations. Neurology 44: S23-S28
11. Koller WC, Hutton JT, Tolosa E, Capilldeo R (1999) Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. Neurology 53: 1012-1019
12. Larsen JP, Worm Petersen J, Siden A, Gordin A, Reinikainen K, Leinonen M and the NOMESAFE Study Group (2003) The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease. Eur J Neurol 10: 137-146
13. Marsden CD, Parkes JD (1976) "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1: 292-296
14. Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson's disease. Lancet 1: 345-349
15. Myllyla V, Kultalahti ER, Haapaniemi H, Leinonen M (2001) Twelve-month safety of entacapone in patients with Parkinson's disease. Eur J Neurol 8: 53-60
16. Nutt JG, Woodward WR, Beckner RM, Stone CK, Berggren K, Carter JH, Gancher ST, Hammerstad JP, Gordin A (1994) Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 44: 913-919
17. Olanow CW, Watts RL, Koller WC (2001) An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 56: S1-S88
18. Pahwa R, Busenbark K, Huber SJ, Michalek D, Hubble JP, Koller WC (1993) Clinical experience with controlled-release carbidopa/levodopa in Parkinson's disease. Neurology 43: 677-681
19. Parkinson Study Group (1997) Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group. Ann Neurol 42: 747-755
20. Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M (2002) Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand 105: 245-255
21. Rajput AH, Fenton ME, Birdi S, Macaulay R, George D, Rozdilsky B, Ang LC, Senthilselvan A, Hornykiewicz O (2002) Clinical-pathological study of levodopa complications. Mov Disord 17: 289-296
22. Reinikainen K, Leiononen M, Isojarvi J, Kaakkola S (2002) Predicting the need for levodopa dose reduction after entacapone initiation in PD patients with end-of-dose wearing-off. Mov Disord 17 [Suppl 5]: S49
23. Rinne UK, Larsen JP, Siden A, Worm-Petersen J (1998) Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 51: 1309-1314
24. Ruottinen HM, Rinne UK (1996) A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson's disease. Clin Neuropharm 19: 283-296
25. Schneider LS, Olin JT (1996) Clinical global impressions in Alzheimer's clinical trials. Int Psychogeriatr 8: 277-288; discussion 288-290
26. Schrag A, Jahanshahi M, Quinn N (2000) How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 15: 1112-1118
27. Wheatley K, Stowew RL, Clarke CE, Hills RK, Williams AC, Gray R (2002) Evaluating drug treatments for Parkinson's disease: how good are the trials? BMJ 324: 1508-1511
28. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, Cherif AA (2002) Nonmotor fluctuations in Parkinson's disease: frequent and disabling. Neurology 59: 408-413
29. World Medical Association (2003) Declaration of Helsinki. www.wma.net/e/policy/b3.htm (accessed May 23, 2003)
30. Zappia M, Oliveri RL, Montesanti R, Rizzo M, Bosco D, Plastino M, Crescibene L, Bastone L, Aguglia U, Gambardella A, Quattrone A (1999) Loss of long-duration response to levodopa over time in PD: implications for wearing-off. Neurology 52: 763-767